Researchers at Xuanwu Hospital have developed an ultrasonic blood test method that detects Alzheimer’s with over 90% accuracy by measuring plasma amyloid-beta seeding activity.
Algocyte has launched the PROXIMA Mobile Health Station, a portable device that uses AI and sensors for at-home blood analysis from finger-prick samples, with UKCA regulatory approval and ongoing evaluation.
Proscia’s Concentriq AP-Dx digital pathology platform has received FDA 510(k) clearance for compatibility with the Leica Aperio GT 450 DX scanner and a Predetermined Change Control Plan to streamline future updates.
The company says its US business combines automated kit manufacturing, fulfillment, sample logistics, and digital workflow technology into a single diagnostic testing platform.
Leica Biosystems received FDA 510(k) clearances for AI-assisted quality control software and two digital pathology scanners, including the first standalone tool to automate QC for digital slides in clinical workflows.
Research presented at ADLM 2026 indicates immunoassays may significantly underestimate HbA1c in patients with sickle cell trait, suggesting HPLC offers more reliable diabetes screening for populations with hemoglobin variants.
The assay is designed to detect minimal residual disease with greater sensitivity than conventional flow cytometry.
The company showcased its latest automation and informatics platforms designed to improve laboratory efficiency and diagnostic accuracy.
USC researchers report that two blood tests, Lumipulse G p-tau217/β-Amyloid 1-42 and PrecivityAD2, can accurately detect Alzheimer’s pathology in patients with Down syndrome.
SCIEX has launched the ExionLC MD system and updated SCIEX OS software, featuring workflow automation and high-performance UHPLC, to help clinical labs improve productivity, as announced at the ADLM meeting.
Astorg has completed its acquisition of Thermo Fisher’s global microbiology business, establishing an independent diagnostics company. Dirk Bontridder has been named CEO.
Zepto Life Technology received up to $8.9 million from NIAID to develop a plasma cell-free DNA liquid biopsy platform aimed at improving diagnosis of invasive fungal infections.
The cobas liat system delivers PCR results in 15 minutes, detecting and differentiating between three Bordetella pathogens including whooping cough.
The automated urinalysis system integrates chemistry and microscopy to help labs manage higher testing volumes and reduce manual reviews to under 3%, according to the company.